Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data

By Reuters News17:33 (UTC), 23 October 2026 Updated

Oct 23 (Reuters) - Roche Holding AG ROPC.S:

ROCHE PRESENTS INTERIM PHASE III DATA SHOWING SEFAXERSEN SIGNIFICANTLY REDUCED PROTEINURIA IN PEOPLE WITH IGA NEPHROPATHY (IGAN)
ROCHE HOLDING AG - SEFAXERSEN ACHIEVED A STATISTICALLY SIGNIFICANT 43.1% REDUCTION IN PROTEINURIA
ROCHE-TREATMENT EFFECT IN ALL PRESPECIFIED SUBGROUPS CONSISTENT WITH CLINICALLY MEANINGFUL REDUCTIONS IN PROTEINURIA SHOWN IN PRIMARY ENDPOINT RESULTS
ROCHE: SEFAXERSEN WAS WELL TOLERATED WITH SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED PHASE II STUDY, EXHIBITING NO NEW SAFETY SIGNALS

Further company coverage: ROPC.S

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.